Obesity Surgery

, Volume 28, Issue 6, pp 1797–1802 | Cite as

Left Gastric Artery Embolisation for the Treatment of Obesity: a Systematic Review

  • Ali Kordzadeh
  • Bruno Lorenzi
  • Muhammad A. Hanif
  • Alexandros Charalabopoulos
New Concept



Endovascular left gastric artery (LGA) embolisation has gained significant attention in the treatment of obesity/morbid obesity and reduction of ghrelin. The objective of this systematic review is to evaluate the recent literature, strengths, limitations and practical aspects of this new procedure in combination with its physiological and anatomical paradigm.


A systematic electronic search of literature from 1966 to June 2017 in Medline, CINHAL, Embase, Scopus and Cochrane library in English language and adult subjects was conducted. This search was conducted in accordance with Preferred Reporting in Systematic Review and Meta-Analysis (PRISMA) guidelines. Quality assessment of the articles was performed, using Oxford critical appraisal skills programme (CASP), and their recommendation for practice was examined through National Institute for health Care Excellence (NICE). Inter-related reliability (Cronbach’s Alpha) was assessed between the two independent reviewers.


A total of n = 62 individuals were subjected to LGA embolisation. At 1–3 months, 7–11% and, at 12 months, 2% weight reduction was associated with ghrelin concentration reduction of 36% at 6 months. There was Haemoglobin A1c reduction (7.4 to 6.3%) and improved quality of life (SF-36 questionnaire) at 6 months (9.5 points) (range, 3.2–17.2). Despite immediate epigastric pain and mucosal ulceration, no long-term adverse outcome was identified. The overall length of stay was 2–3 days.


The outcome of this review (level of evidence 3) suggests LGA embolisation is feasible and effective and perhaps a safe procedure in the treatment of obesity and reduction of ghrelin. However, further trials are highly advocated.


Left gastric artery (LGA) Gastric artery embolisation (GAE) Obesity Morbid obesity Bariatrics Systematic review 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed Consent

Not applicable

Statement of Human and Animal Rights

Not applicable


  1. 1.
    Remedios C, Bhasker AG, Dhulla N. Bariatric nutrition guidelines for the Indian population. Obese Surg. 2016;26:1057–68.CrossRefGoogle Scholar
  2. 2.
    Stegenga H, Haines A, Jones K, et al. Guidelines development group, identification, assessment and management of overweight and obesity; summary of the updated NICE guidelines. BMJ. 2014;349:g608.CrossRefGoogle Scholar
  3. 3.
    Masters RK, Reither EN, Powers DA, et al. The impact of obesity on USA mortality levels; the importance of age and cohort factors in population estimates. Am J Public Health. 2013;103:1895–901.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Anton K, Rahman T, Bhanushali A, et al. Bariatric left gastric artery embolization for the treatment of obesity: a review of gut hormone involvement in energy homeostasis. AJR Am J Roentgenol. 2016;206(1):202–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    CASP Critical Appraisal Skills Programme OXFORD UK;
  7. 7.
    Weightman A, Ellis S, Cullum A, Sander L, Turley R. Grading evidence and recommendation for public health interventions: developing ad piloting a framework
  8. 8.
    Weiss CR, Akinwande O, Paudel K, et al. Clinical safety of bariatric arterial embolization: preliminary results of the BEAT obesity trial. Radiology. 2017;283(2):598–608.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Salsamendi J, Pereira K, Kang K, Fan J. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report. J Radiol Case Rep 2015 30;9(9):36–43.Google Scholar
  10. 10.
    Gunn AJ, Oklu R. A preliminary observation of weight loss following left gastric artery embolization in humans. J Obes. 2014:185349.Google Scholar
  11. 11.
    Kipshidze N, Archvadze A, Betrog S, et al. Endovasculsar bariatrics first in human study of gastric artery embolisation for weight loss. JACC Cardiovasc Interv. 2015;8:1641–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Syed MI, Morar K, Shaikh A, et al. Gastric artery embolization trials for lessening of appetite nonsurgically; six month preliminary data. J Vasc Interv Radiol. 2016;27:1502–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 2004;18(3):439–56.CrossRefPubMedGoogle Scholar
  14. 14.
    Weiss CR, Gunn AJ, Kim CY, et al. Bariatric embolization of the gastric arteries for the treatment of obesity. J Vasc Interv Radiol. 2015;26(5):613–24.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Prochaska JM, Flye MW, Johnsrude IS. Left gastric artery embolization for control of gastric bleeding; a complication. Radiology. 1973;107:521–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Vaidya S, Tozer KR, Chen J. An overview of embolic agents. Semin Intervent Radiol. 2008;25(3):204–15.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    National institute of clinical excellence (NICE) Guidelines. Obesity: Identification, Assessment and management. CG189. 2014. Available at:
  18. 18.
    Perry B, Wang Y. Appetite regulation and weight control: the role of gut hormones. Nutr Diabetes. 2012;2e:e26.CrossRefGoogle Scholar
  19. 19.
    Cumming DE, Overduin J. Gastrointestinal regulation of the food intake. J Clin Invest. 2007;117:13–23.CrossRefGoogle Scholar
  20. 20.
    Kalinowski P, Paluszkiewicz R, Wroblewski T, et al. Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus roux-en-Y gastric bypass-results of a randomized clinical trial. Surg Obes Relat Dis. 2017;13(2):181–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Santo MA, Riccioppo D, Pakecki D, et al. Weight regain after gastric bypass: influence of gut hormones. Obes Surg. 2016;26(5):919–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Terra X, Auguet T, Guiu-Jurado E, et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23(11):1790–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Vascular, Endovascular and Renal AccessMid Essex Hospitals Services NHS TrustBroomfieldUK
  2. 2.Broomfield HospitalEssexUK
  3. 3.Department of General and Upper Gastrointestinal Surgery, Regional Oesophagogastric CentreMid Essex Hospitals Services NHS TrustBroomfieldUK
  4. 4.Department of Interventional RadiologyMid Essex Hospitals Services NHS TrustBroomfieldUK

Personalised recommendations